This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen
by Zacks Equity Research
Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
by Indrajit Bandyopadhyay
Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
The Zacks Analyst Blog Highlights Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan
by Zacks Equity Research
Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.
Top Research Reports for Novo Nordisk, AMD & Netflix
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).
4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.
The Zacks Analyst Blog Highlights Apple, The Procter & Gamble, Chevron, Novo Nordisk and Canadian Natural Resources Limited
by Zacks Equity Research
Apple, The Procter & Gamble, Chevron, Novo Nordisk and Canadian Natural Resources Limited have been included in this Analyst Blog.
Top Analyst Reports for Apple, P & G, Chevron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), The Procter & Gamble Company (PG), and Chevron Corporation (CVX).
Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion
by Zacks Equity Research
The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.
BAYRY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAYRY vs. NVO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: The Procter & Gamble Co., Chevron Corp., Novo Nordisk A/S, FedEx Corp. and Palo Alto Networks, Inc
by Zacks Equity Research
The Procter & Gamble Co., Chevron Corp., Novo Nordisk A/S, FedEx Corp. and Palo Alto Networks, Inc are highlighted in this Analyst Blog.
Top Stock Reports for Procter & Gamble, Chevron & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Chevron Corporation (CVX), and Novo Nordisk A/S (NVO).
Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO
by Indrajit Bandyopadhyay
Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.
GSK vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. NVO: Which Stock Is the Better Value Option?
Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal
by Zacks Equity Research
Lilly (LLY) inks a strategic collaboration with Regor Therapeutics to discover and develop novel therapies for metabolic disorders.
The Zacks Analyst Blog Highlights: Netflix, Salesforce, Novo Nordisk, Caterpillar and ConocoPhillips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Salesforce, Novo Nordisk, Caterpillar and ConocoPhillips
Top Research Reports for Netflix, salesforce & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), salesforce.com, inc. (CRM), and Novo Nordisk (NVO).
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
GSK vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion
by Zacks Equity Research
Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk